- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
January 27th, 2005
Starpharma shares soared yesterday after the nanotechnology group confirmed that it had signed a strategic and potentially lucrative deal with The Dow Chemical Company.
Under the three-way deal, Starpharma's US-based subsidiary, Dendritic NanoTechnologies (DNT), will acquire Dow's extensive portfolio of patents covering dendrimer technology. It also gains the rights to revenue from Dow's already established licensing activities.
|Related News Press|
Aspen Aerogels to Present at the 28th Annual ROTH Conference March 14th, 2016
Arrowhead to Present at Upcoming March Conferences March 1st, 2016
Arrowhead to Webcast Fiscal 2015 Year End Results December 7th, 2015
Haydale Announce Year End Results November 3rd, 2015